These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38701024)

  • 41. Use of the Prostacyclin Receptor Agonist Selexipag in Patients With Pulmonary Arterial Hypertension Associated With Eisenmenger Syndrome.
    Demerouti EA; Karyofyllis P; Apostolopoulou SC
    Can J Cardiol; 2021 Aug; 37(8):1286-1288. PubMed ID: 33539988
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Costs vs. benefit: How much combination therapy of pulmonary arterial hypertension can we afford to pay?].
    Grünig E
    Dtsch Med Wochenschr; 2009 Aug; 134 Suppl 5():S176. PubMed ID: 19718610
    [No Abstract]   [Full Text] [Related]  

  • 43. Cost-utility of ambrisentan and bosentan for pediatric pulmonary arterial hypertension.
    Buendia JA; Patino DG; Lindarte EF
    Expert Rev Pharmacoecon Outcomes Res; 2023; 23(8):967-973. PubMed ID: 37403496
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Practical management of riociguat in patients with pulmonary arterial hypertension.
    Halank M; Tausche K; Grünig E; Ewert R; Preston IR
    Ther Adv Respir Dis; 2019; 13():1753466619868938. PubMed ID: 31438774
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacotherapy for pulmonary arterial hypertension.
    Burki TK
    Lancet Respir Med; 2020 Nov; 8(11):e81. PubMed ID: 32857988
    [No Abstract]   [Full Text] [Related]  

  • 46. Cost-benefit of treating hypertension.
    Jönsson BG
    J Hypertens Suppl; 1994 Dec; 12(10):S65-70. PubMed ID: 7769494
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Diagnosis of pulmonary arterial hypertension preceding the confirmation of systemic sclerosis in a patient with Raynaud's phenomenon.
    Tariq S; Tervaert JWC; Osman M
    Microvasc Res; 2022 Jan; 139():104267. PubMed ID: 34666100
    [No Abstract]   [Full Text] [Related]  

  • 48. Right Ventricle-Specific Three-Dimensional Wall Motion Tracking for Visualization of Regional Wall Motion Abnormality in Patients With Pulmonary Arterial Hypertension.
    Moriyama H; Murata M; Kataoka M; Kawakami T; Endo J; Kohno T; Itabashi Y; Seo Y; Iwao Y; Fukuda K
    Circ Cardiovasc Imaging; 2019 Apr; 12(4):e008795. PubMed ID: 30939920
    [No Abstract]   [Full Text] [Related]  

  • 49. Counterpoint: Should the Use of Upfront Triple Combination Therapy Be Standard of Care in Pulmonary Arterial Hypertension? No.
    Sahay S
    Chest; 2024 Mar; 165(3):494-496. PubMed ID: 38461012
    [No Abstract]   [Full Text] [Related]  

  • 50. POINT: Should the Use of Upfront Triple Combination Therapy Be Standard of Care in Pulmonary Arterial Hypertension? Yes.
    Weatherald J; Sitbon O
    Chest; 2024 Mar; 165(3):492-494. PubMed ID: 38461011
    [No Abstract]   [Full Text] [Related]  

  • 51. Living With Severe Pulmonary Arterial Hypertension Without an Infusion Pump? Selexipag has a Role to Play.
    Lázaro Salvador M; Akerström F; Escribano Subías P; Berenguel Senén A; Martinez Mateo V; Rodriguez Padial L
    Arch Bronconeumol (Engl Ed); 2019 Feb; 55(2):102-103. PubMed ID: 30060983
    [No Abstract]   [Full Text] [Related]  

  • 52. Ambrisentan for in pediatric pulmonary arterial hypertension: A cost-utility analysis.
    Buendía JA; Patiño DG; Lindarte EF
    Pediatr Pulmonol; 2023 May; 58(5):1562-1568. PubMed ID: 36797849
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effectiveness and safety of endothelin receptor antagonists, alone and in combination therapy, in the pulmonary arterial hypertension-connective tissue disease subtype: A systematic review and meta-analysis.
    Shivakumar S; Thynne TR; Mohammadi L; Burdeniuk C; Mangoni AA
    Int J Rheum Dis; 2020 Oct; 23(10):1276-1287. PubMed ID: 32691518
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cost per millimeter of mercury lowering is a measure of economic value for antihypertensive agents.
    Chen RS; Lapuerta P
    Curr Hypertens Rep; 2000 Dec; 2(6):525-9. PubMed ID: 11062597
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phosphodiesterase 5 Inhibitor for Pediatric Pulmonary Arterial Hypertension: A Cost-Utility Analysis.
    Buendía JA; Lindarte EF; Guerrero Patiño D
    Value Health Reg Issues; 2023 Jul; 36():44-50. PubMed ID: 37028260
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Search for Disease-Modifying Therapies in Pulmonary Hypertension.
    Woodcock CC; Chan SY
    J Cardiovasc Pharmacol Ther; 2019 Jul; 24(4):334-354. PubMed ID: 30773044
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Merck bets on sotatercept in pulmonary arterial hypertension.
    Carvalho T
    Nat Med; 2023 Jan; 29(1):2-3. PubMed ID: 36396929
    [No Abstract]   [Full Text] [Related]  

  • 58. Identification of factors driving differences in cost effectiveness of first-line pharmacological therapy for uncomplicated hypertension.
    Klarenbach SW; McAlister FA; Johansen H; Tu K; Hazel M; Walker R; Zarnke KB; Campbell NR;
    Can J Cardiol; 2010 May; 26(5):e158-63. PubMed ID: 20485695
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Public funding of bosentan for the treatment of pulmonary artery hypertension in Australia: cost effectiveness and risk sharing.
    Wlodarczyk JH; Cleland LG; Keogh AM; McNeil KD; Perl K; Weintraub RG; Williams TJ
    Pharmacoeconomics; 2006; 24(9):903-15. PubMed ID: 16942124
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Outcome of paediatric portopulmonary hypertension in the modern management era: A case report of 6 patients.
    Joye R; Lador F; Aggoun Y; Farhat N; Wacker J; Wildhaber BE; Vallée JP; Hachulla AL; McLin VA; Beghetti M
    J Hepatol; 2021 Mar; 74(3):742-747. PubMed ID: 33276028
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.